Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 1001-1008

  Altenschmidt, Uwe ^a   Kahl, Ralf ^a   Moritz, Dirk ^a   Schnierle, Barbara S ^a   Gerstmayer, Bernhard ^a   Wels, Winfried ^a   Groner, Bernd ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL;

3T3 CELLS; ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE THERAPY; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 0029948642     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991.
2. Old, L. J. Cancer immunology: the search for specificity. Cancer Res., 41: 361-375, 1981.
3. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E , Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognition by cytolytic T lymphocytes an a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
4. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 209; 1281-1284, 1995.
5. Rosenberg, S. A. Immunotherapy and gene therapy of cancer. Cancer Res. 51 (Suppl): 5074s-5079s, 1991.
6. Chang, A. E., and Shu, S. Immunotherapy with sensitized lymphocytes. Cancer Invest., 10: 357-369, 1992.
7. Kast, M. W., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J , and Melief, C. J. M. Eradication of adenovirus El-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell, 59: 603-614, 1989.
8. Aebersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanders, M., Lotze, M., Topalian, S., Yang, J., and Rosenberg, S. A. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst., 83: 932-937, 1991
9. Fox, B. A., and Rosenberg, S. A. Heterogeneous lymphokine activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. Cancer Immunol. Immunother., 29: 155-166, 1989.
10. Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A , Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., Merino, M. J., Culver, K., Miller, A. D., Blaese, R. M., and Anderson, W. F. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323: 601-603, 1990.
11. Davis, M. M , and Bjorkman, P. J. T-cell antigen receptor genes and T-cell recognition. Nature (Lond.), 334: 395-402, 1988.
12. Klausner, R. D., and Samelson, L. E. T cell antigen receptor activation pathways: the tyrosine kinase connection. Cell, 64: 875-878, 1991.
13. Frank, S. J., Niklinska, B. B., Orloff, D. G., Mercep, M., Ashwell, J. D., and Klausner, R. D. Structural mutations of the T cell receptor ζ chain and its role in T cell activation. Science (Washington DC), 249: 174-177, 1990.
14. Weiss, A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein tyrosine kinases. Cell, 73: 209-213, 1993.
15. Weiss, A., and Littman, D. R. Signal transduction by lymphocyte antigen receptors. Cell, 76: 263-274, 1994.
16. Brocker, T., and Karjalainen, K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med., 181: 1653-1659, 1995.
17. Moritz, D , Wels, W., Mattern, J., and Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA, 91: 4318-4322, 1991.
18. Romeo, C., and Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell, 64: 1037-1046, 1991.
19. Eshhar, Z., Waks, T., Gross, G., and Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 90: 720-724, 1993.
20. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
21. Semba, K., Kamata, N., Toyoshima, K., and Yamamoto, T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/ epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. USA, 82: 6497-6501, 1985.
22. Fukushige, S. I., Matsubara, K., Yoshida, M., Sasaki, T., Semba, K., Toyoshima, K., and Yamamoto, T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol. Cell. Biol., 6: 955-958, 1986.
23. Peles, E., and Yarden, Y. Neu and its ligands: from an oncogene to neural factors. BioEssays, 15: 815-824, 1993.
24. Hynes, N. E., and Stem, D. F. The biology of erbB-2/neu/Her-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
25. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA, 86: 9193-9197, 1989.
26. Lemoine, N. R., Barnes, D. M., Hollywood, D. P., Hughes, C. M., Smith, P., Dublin, E., Prigent, S. A., Gullick, W. J., and Hurst, H. C. Expression of the ERBB3 gene product in breast cancer. Br. J. Cancer, 66: 1116-1121, 1992.
27. Plowman, G. D., Culouscu, J. M., Whitney, G. S., Green, J. M., Carlton, G. M., Foy, L., Neubauer, M. G., and Shoyab, M. Ligand-specific activation of Her4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA, 90: 1746-1750, 1993.
28. Plowman, G. D., Green, J. M., Culouscu, J. M., Carlton, G. M., Rothwell, V. M., and Buckley, S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature (Lond.), 366: 473-475, 1993.
29. Moritz, D., and Groner, B. A spacer region between the single chain antibody- and the CD3 ζ-chain domain of chimeric T-cell receptor components is required for efficient ligand binding signaling activity. Gene Ther., 2: 539-546, 1995.
30. Eichmann, K., Ehrfeld, A., Falk, I., Goebel, H., Kupsch, J., Reimann, A., Zgaga-Griesz, A., Saizawa, K M., Yachelini, P., and Tomonari, K. Affinity enhancement and transmembrane signalling are associated with distinct epitopes on the CD8 αβ heterodimer. J. Immunol., 147: 2075-2081, 1991.
31. Karasuyama, H., and Melchers, F. Establishment of mouse cell line which constitutively secrete large quantities of interleucin 2, 3, 4, or 5, using modified cDNA expression vectors. Eur. J. Immunol., 18: 97-104, 1988.
32. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
33. Miller, A. D., and Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-990, 1989.
34. Hynes, N. E., Taverna, D., Harwerth, I. M., Ciardiello, F., Salomon, D. S., Yamamoto, T., and Groner, B. Epidermal growth factor, but not c-erbB-2, activation prevents lactogenic hormone induction of the β-casein gene in mouse mammary epithelial cells. Mol. Cell. Biol., 10: 4027-4034, 1990.
35. Yarden, Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA, 87: 2569-2573, 1990.
36. Harwerth, I. M., Weis, W., Marte, B. M., and Hynes, N. E. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonist. J. Biol. Chem., 267: 15160-15167, 1992.
37. Weis, W., Harwerth, I. M., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52: 6310-6317, 1992.
38. Meyer, H., Osterrieder, N., and Czerny, C-P. Identification of binding sites for neutralizing monoclonal antibodies on the 14 kDa fusion protein of orthopox viruses. Virology, 22: 778-783, 1994.
39. Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., and Lewis, G. D. Identification of heregulin, a specific activator of p185erbB2. Science (Washington DC), 256: 1205-1210, 1992.
40. Jeschke, M., Weis, W., Dangler, W., Imber, R., Stocklin, E., and Groner, B. Target inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer, 60: 730-739, 1995.
41. Weissmann, A. M., Baniyash, M., Hou, H., Samelson, L. E., Burgess, W. H., and Klausner, R. D. Molecular cloning of the ζ chain of the T cell antigen receptor. Science (Washington DC), 239: 1018-1021, 1988.
42. Evan, G. I., Lewis, G. K., Ramsay, G., and Bishop, J. M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol., 5: 3610-3616, 1985.
43. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. (eds.). Current Protocols in Immunology, Vol. 2, pp. 3.2.1-3.2.3. New York: J. Wiley & Sons, Inc., 1993.
44. Brett, S. J., Mazurov, A. V., Charles, I. G., and Tite, J. P. The invasin protein of Yersinia spp. provides co-stimulatory activity to human T cells through interaction with β1 integnns. Eur. J. Immunol., 23: 1608-1614, 1993.
45. + human T cell subsets derived from TIL and PBMC. Cancer Immunol. Immunother., 32: 342-352, 1991.
46. Culver, K., Cornetta, S., Rorgan, S., Morecki, S., Aebersold, P., Blaese, M., Anderson, W. F., and Rosenberg, S. A. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc. Natl. Acad. Sci. USA, 88: 3155-3159, 1991.
47. Mavilio, F., Ferrari, G., Rossini, S., Nobili, N., Bonini, C., Casorata, G., Traversari, C., and Bordigon, C. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood, 50: 1988-1997, 1994.
48. Staal, F. J. T., Rees, P. C M., Weijer, K., and Spits, H. Development of retroviral cells into mature thymocytes. Int. Immunol., 7: 1301-1309, 1995.
49. Hwu, P., Yang, J. C., Cowherd R., Treisman, J., Shafer, G. E., Eshhar, Z., and Rosenberg, S. A. In vitro antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res., 55: 3369-3373, 1995.
50. Sprent, J., and Tough, D. F. Lymphocyte life-span and memory. Science (Washington DC), 265: 1395-1397, 1994.
51. Letourneur, F., and Klausner, R. D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor ζ family proteins. Proc. Natl. Acad. Sci. USA, 88: 8905-8909, 1991.
52. Irving, B. A., and Weiss, A. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell, 64: 891-901, 1991.